Levin Capital Strategies L.P. Reduces Holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Key Points

• Levin Capital Strategies L.P. reduced its holdings in Alpha Tau Medical by 29.3%, selling 92,000 shares and bringing its ownership to approximately $559,000.
• HC Wainwright has maintained a "buy" rating for Alpha Tau Medical, setting a target price of $9.00 per share.
• Alpha Tau Medical reported an earnings per share of ($0.12) for the recent quarter, surpassing analyst expectations of ($0.14).

Levin Capital Strategies L.P. decreased its position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 29.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,514 shares of the company's stock after selling 92,000 shares during the quarter. Levin Capital Strategies L.P. owned about 0.32% of Alpha Tau Medical worth $559,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC grew its holdings in Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after buying an additional 26,800 shares in the last quarter. Northern Trust Corp grew its holdings in Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after buying an additional 25,770 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Alpha Tau Medical in the first quarter worth $53,000. Institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Stock Performance

DRTS stock traded up $0.12 during midday trading on Friday, hitting $3.39. The company's stock had a trading volume of 96,722 shares, compared to its average volume of 46,499. The stock's 50-day moving average price is $3.06 and its 200 day moving average price is $2.94. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.10. Alpha Tau Medical Ltd. has a 1 year low of $2.06 and a 1 year high of $4.39. The stock has a market cap of $287.54 million, a price-to-earnings ratio of -7.37 and a beta of 0.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings results on Monday, May 19th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. On average, equities analysts forecast that Alpha Tau Medical Ltd. will post -0.45 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.

Alpha Tau Medical Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.